Analyst Price Targets — ONC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 12:11 pm | Kalpit Patel | Wolfe Research | $370.00 | $358.38 | TheFly | BeOne Medicines price target raised to $370 from $340 at Wolfe Research |
| August 6, 2026 9:08 am | — | Barclays | $407.00 | $327.53 | TheFly | BeOne Medicines price target raised to $407 from $403 at Barclays |
| July 14, 2026 9:39 am | — | Barclays | $403.00 | $303.96 | TheFly | BeOne Medicines price target lowered to $403 from $409 at Barclays |
| July 13, 2026 1:01 am | — | Jefferies | $380.00 | $298.70 | TheFly | BeOne Medicines upgraded to Buy from Hold at Jefferies |
| July 7, 2026 1:13 pm | — | Truist Financial | $416.00 | $308.46 | TheFly | BeOne Medicines price target raised to $416 from $413 at Truist |
| July 7, 2026 11:29 am | — | RBC Capital | $451.00 | $309.46 | TheFly | BeOne Medicines price target raised to $451 from $436 at RBC Capital |
| June 2, 2026 11:16 am | Leonid Timashev | RBC Capital | $436.00 | $276.47 | StreetInsider | BeOne Medicines (ONC) PT Raised to $436 at RBC Capital |
| May 15, 2026 2:56 pm | — | Leerink Partners | $367.00 | $293.76 | TheFly | BeOne Medicines price target raised to $367 from $364 at Leerink |
| May 7, 2026 1:15 pm | — | Morgan Stanley | $395.00 | $312.05 | TheFly | BeOne Medicines price target raised to $395 from $389 at Morgan Stanley |
| May 7, 2026 10:41 am | Michael Schmidt | Guggenheim | $420.00 | $313.32 | TheFly | BeOne Medicines price target raised to $420 from $410 at Guggenheim |
Latest News for ONC
Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company's website at…
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement…
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally…
Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ONC.
U.S. House Trading
No House trades found for ONC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.